Skip to main content

Table 1 Baseline clinical characteristics

From: Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma

Patient characteristic DP group
(n = 103)
S-1 group
(n = 72)
p value
Age (median, year) 62 64 0.647
 < 60 48 (46.6%) 31 (43.1%)  
 ≥ 60 55 (53.4%) 41 (56.9%)  
Gender    0.873
Male 65 (63.1%) 47 (65.3%)  
Female 38 (36.9%) 25 (34.7%)  
KPS    0.756
90 43 (41.7%) 28 (38.9%)  
 ≥ 70 60 (58.3%) 44 (61.1%)  
Tumor location    0.394
Upper third 28 (27.2%) 16 (22.2%)  
Middle third 60 (58.3%) 40 (55.6%)  
Lower third 15 (14.5%) 16 (22.2%)  
Primary tumor length (cm)    0.759
 < 5 56 (54.4%) 41 (56.9%)  
 ≥ 5 47 (45.6%) 31 (43.1%)  
Smoking    0.273
Nonsmoker 43 (41.7%) 24 (33.3%)  
Smoker 60 (58.3%) 48 (66.7%)  
Drinking    0.358
No 49 (47.6%) 29 (40.3%)  
Yes 54 (52.4%) 43 (59.7%)  
Differentiation    0.838
Well 14 (13.6%) 8 (11.1%)  
Moderate 59 (57.3%) 44 (61.1%)  
Poor 30 (29.1%) 20 (27.7%)  
Clinical T stage    1.000
No invasion to adjacent organs 56 (54.4%) 39 (54.2%)  
Invasion to adjacent organs 47 (45.6%) 33 (45.8%)  
Clinical N stage    0.867
N0 30 (29.1%) 20 (27.8%)  
N1 73 (70.9%) 52 (72.2%)  
Reason for no surgery    0.924
Patient refusal 8 (7.7%) 6 (8.3%)  
Surgical contraindication 15 (14.6%) 9 (12.5%)  
Unresectable disease 65 (63.1%) 44 (61.1%)  
Unknown 15 (14.6%) 13 (18.1%)  
Radiation dose (Gy)    0.698
50 34 (33.0%) 23 (31.9%)  
50.4 46 (44.7%) 29 (40.3%)  
 > 50.4 23 (22.3%) 20 (27.8%)  
Radiotherapy techniques    0.410
3D-CRT 30 (29.1%) 26 (36.1%)  
IMRT 73 (70.9%) 46 (63.9%)  
Consolidation chemotherapy    0.537
Yes 61 (59.2%) 39 (54.2%)  
No 42 (40.8%) 33 (45.8%)  
Nutritional support    0.265
Yes 17 (16.5%) 7 (9.7%)  
No 86 (83.5%) 65 (90.3%)  
  1. KPS Karnofsky performance status, 3D-CRT three-dimensional conformal radiotherapy, IMRT intensity modulated radiotherapy